13F Holdings
中文EN

BTAIQ BioXcel Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1720893 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.5%
TTM net income YoY-39.1%
TTM EPS YoY78.3%
Revenue 3-yr CAGR-10.6%
Net income 3-yr CAGR—

Margins

Gross margin53.1%
Operating margin-6,054.7%
Net margin-9,549.9%
FCF margin-6,860.4%
EBITDA margin-6,024.4%

Returns

ROE—
ROA-259.6%
ROIC (approx.)—
Asset turnover0.03x

Leverage & solvency

Liabilities / assets500.9%
Debt / equity—
Current ratio0.21x
Interest coverage-2.61x

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-73.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$642,000$2.27M$1.38M$375,000—
Cost of revenue$164,000$2.14M$1.26M$20,000—
Gross profit$478,000$123,000$120,000$355,000—
R&D expense$30.25M$30.43M$84.33M$91.24M$52.71M
SG&A expense$20.49M$34.49M$83.41M$68.76M$54.23M
Operating income-$50.46M-$67.25M-$171.78M-$159.65M-$106.94M
Interest expense$16.98M$15.13M$13.31M$8.21M$40,000
Income tax$0$0$0——
Net income-$69.90M-$59.60M-$179.05M-$165.76M-$106.93M
EBITDA-$50.16M-$66.94M-$171.46M-$159.32M-$106.64M
EPS (basic)-5.73-23.51-98.33-5.92-4.05
EPS (diluted)-5.73-23.51-98.33-5.92-4.05
Weighted avg. shares (diluted)12.21M2.54M1.82M28.02M26.37M
Balance sheet
Cash & equivalents$28.41M$29.85M$65.22M$193.72M$232.97M
Receivables$233,000$131,000$71,000$248,000—
Inventory$722,000$679,000$1.99M$1.99M—
Current assets$44.69M$37.39M$72.14M$202.87M$236.81M
PP&E, net$175,000$475,000$784,000$1.08M$1.29M
Total assets$44.92M$38.34M$73.70M$205.85M$239.44M
Current liabilities$53.93M$22.23M$27.27M$32.90M$16.67M
Short-term debt$24.93M$0———
Long-term debt$84.66M$102.51M$100.60M$93.05M—
Total debt$109.59M$102.51M$100.60M$93.05M—
Total liabilities$140.38M$131.44M$130.21M$129.08M$17.77M
Shareholders' equity-$95.46M-$93.10M-$56.51M$76.78M$221.67M
Net debt$81.18M$72.65M$35.38M-$100.67M—
Shares outstanding22.33M3.10M1.87M28.15M27.98M
Cash flow statement
Operating cash flow-$57.62M-$72.03M-$155.01M-$135.34M-$82.15M
Capital expenditure$0$0$20,000$139,000$445,000
Free cash flow-$57.62M-$72.03M-$155.03M-$135.48M-$82.60M
Investing cash flow$0$0-$20,000-$139,000-$445,000
Financing cash flow$56.52M$36.66M$26.52M$96.24M$102.45M
Depreciation & amortization$300,000$309,000$318,000$327,000$297,000
Stock-based compensation$2.77M$6.16M$18.61M$17.34M$19.45M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.